Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

 

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in immuno-oncology, today provides an update on its recent operations and reported consolidated financial results for the twelve-month period ended 31 December 2016, prepared in accordance with IFRS

Key 2016 Highlights

  • Completion of first CAR-T NKR-2 Phase I trial, confirming safety of CAR-T NKR-2 cells but also reporting unexpected clinical activity in patients suffering from AML and MM.
  • Signature of strategic collaboration agreements with ONO Pharmaceuticals and Institut Curie to support development of immuno-oncology programs.
  • Approval from Belgian regulatory authorities to start THINK Phase I trial in Belgium.
  • Release of CHART-1 data 9-month primary endpoint. Results for the CHART-1 European Phase III clinical trial evaluating C-Cure® cell therapy did not meet the primary endpoint
  • Strong cash position: EUR 82.6 million as of 31 December 2016.


Expected 2017 Milestones

  • Initiation of THINK trial (USA) in Q1 2017.
  • Initiation of SHRINK study (US/EU) in Q2 2017.
  • Initiation of LINK study (EU) in Q3 2017.
  • THINK dose-escalation results expected in Q4 2017.

 

 

 

Commenting on the 2016 results, Christian Homsy, CEO of Celyad, said:

“2016 has been a challenging year in which our CAR-T portfolio has continued to develop, with the company building its expertise in the field of immuno-oncology, and one in which we transitioned from a focus on cardiology to being one of the most promising prospects in the field of next generation CAR-T cells.”

Note

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized cell- based therapies. The Company utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR-2, has been evaluated in a single dose - escalation Phase I clinical trial to assess the safety and feasibility of CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase I study was successfully completed in September 2016. Celyad was founded in 2007 and is based in Mont-Saint Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on NASDAQ Global Market, all under the ticker symbol CYAD. For more information about Celyad, please visit: www.celyad.com

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?